307 related articles for article (PubMed ID: 24009228)
1. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
Ott G; Rosenwald A; Campo E
Blood; 2013 Dec; 122(24):3884-91. PubMed ID: 24009228
[TBL] [Abstract][Full Text] [Related]
2. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
Ott G; Rosenwald A; Campo E
Hematology Am Soc Hematol Educ Program; 2013; 2013():575-83. PubMed ID: 24319234
[TBL] [Abstract][Full Text] [Related]
3. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
[TBL] [Abstract][Full Text] [Related]
4. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
5. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
6. Impact of MYC on malignant behavior.
Ott G
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):100-6. PubMed ID: 25696841
[TBL] [Abstract][Full Text] [Related]
7. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.
Turakhia SK; Hill BT; Dufresne SD; Nakashima MO; Cotta CV
Am J Clin Pathol; 2014 Sep; 142(3):339-46. PubMed ID: 25125624
[TBL] [Abstract][Full Text] [Related]
8. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.
Cai Q; Medeiros LJ; Xu X; Young KH
Oncotarget; 2015 Nov; 6(36):38591-616. PubMed ID: 26416427
[TBL] [Abstract][Full Text] [Related]
9. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
10. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
11. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
12. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
13. MYC alterations in diffuse large B-cell lymphomas.
Karube K; Campo E
Semin Hematol; 2015 Apr; 52(2):97-106. PubMed ID: 25805589
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
Kim H; Kim HJ; Kim SH
Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
17. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
18. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
19. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.
Zhang J; Weng Z; Huang Y; Li M; Wang F; Wang Y; Rao H
Am J Surg Pathol; 2020 Dec; 44(12):1602-1611. PubMed ID: 32991338
[TBL] [Abstract][Full Text] [Related]
20. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
Sesques P; Johnson NA
Blood; 2017 Jan; 129(3):280-288. PubMed ID: 27821509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
